PT689449E - Composicoes para aplicacao em terapeutica humana caracterizadas pela associacao de um peptido de muramilo a uma citoquina - Google Patents

Composicoes para aplicacao em terapeutica humana caracterizadas pela associacao de um peptido de muramilo a uma citoquina

Info

Publication number: PT689449E
Authority: PT; Portugal
Prior art keywords: pct; muramilo; citoquin; peptide; association
Prior art date: 1993-03-19

Application number

PT94910445T

Other languages

English (en)

Inventor

Georges Bahr

Pierre Lefrancier

Louis Chedid

Original Assignee

Vacsyn Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-03-19

Filing date

1994-03-21

Publication date

2003-03-31

1993-03-19 Priority claimed from FR9303230A external-priority patent/FR2702659B1/fr

1993-03-31 Priority claimed from FR9303787A external-priority patent/FR2703251B3/fr

1994-03-21 Application filed by Vacsyn Sa filed Critical Vacsyn Sa

2003-03-31 Publication of PT689449E publication Critical patent/PT689449E/pt

Links

239000000203 mixture Substances 0.000 title abstract 3
108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
239000003814 drug Substances 0.000 title 1
238000001727 in vivo Methods 0.000 abstract 2
108090000695 Cytokines Proteins 0.000 abstract 1
102000004127 Cytokines Human genes 0.000 abstract 1
101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 abstract 1
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 abstract 1
102000014150 Interferons Human genes 0.000 abstract 1
108010050904 Interferons Proteins 0.000 abstract 1
108010002352 Interleukin-1 Proteins 0.000 abstract 1
102000000589 Interleukin-1 Human genes 0.000 abstract 1
102000051628 Interleukin-1 receptor antagonist Human genes 0.000 abstract 1
108090001007 Interleukin-8 Proteins 0.000 abstract 1
230000000259 anti-tumor effect Effects 0.000 abstract 1
230000000840 anti-viral effect Effects 0.000 abstract 1
230000003394 haemopoietic effect Effects 0.000 abstract 1
210000000987 immune system Anatomy 0.000 abstract 1
229940079322 interferon Drugs 0.000 abstract 1
125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 abstract 1
230000001737 promoting effect Effects 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Cardiology (AREA)
Transplantation (AREA)
Virology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PT94910445T 1993-03-19 1994-03-21 Composicoes para aplicacao em terapeutica humana caracterizadas pela associacao de um peptido de muramilo a uma citoquina PT689449E (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9303230A FR2702659B1 (fr)	1993-03-19	1993-03-19	Compositions pour l'application en thérapeutique humaine, caractérisées par l'association d'un muramyl-peptide à une cytokine.
FR9303787A FR2703251B3 (fr)	1993-03-31	1993-03-31	Compositions pour l'application en thérapeutique humaine, caractérisées par l'association d'un muramyl-peptide à une cytokine .

Publications (1)

Publication Number	Publication Date
PT689449E true PT689449E (pt)	2003-03-31

Family

ID=26230187

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT94910445T PT689449E (pt)	1993-03-19	1994-03-21	Composicoes para aplicacao em terapeutica humana caracterizadas pela associacao de um peptido de muramilo a uma citoquina

Country Status (11)

Country	Link
US (1)	US5932208A (pt)
EP (1)	EP0689449B1 (pt)
JP (1)	JP3723206B2 (pt)
AT (1)	ATE226828T1 (pt)
AU (1)	AU6285694A (pt)
CA (1)	CA2157758A1 (pt)
DE (1)	DE69431620T2 (pt)
DK (1)	DK0689449T3 (pt)
ES (1)	ES2187520T3 (pt)
PT (1)	PT689449E (pt)
WO (1)	WO1994021275A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5075222A (en)	1988-05-27	1991-12-24	Synergen, Inc.	Interleukin-1 inhibitors
US6159460A (en) *	1988-05-27	2000-12-12	Amgen Inc.	Method for treating interleukin-1 mediated diseases
US6858409B1 (en)	1988-05-27	2005-02-22	Amgen Inc.	Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US6267968B1 (en) *	1995-04-07	2001-07-31	Vacsyn S.A.	MDP derivatives and conjugates having haematipoietic function stimulating activity, and compositions containing same
JP4771563B2 (ja)	1996-12-06	2011-09-14	アムジエン・インコーポレーテツド	Ｉｌ−１媒介疾患を処置するためにｉｌ−１インヒビターを使用する組合せ療法
US6294170B1 (en)	1997-08-08	2001-09-25	Amgen Inc.	Composition and method for treating inflammatory diseases
US6013253A (en) *	1997-08-15	2000-01-11	Amgen, Inc.	Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
US8106098B2 (en)	1999-08-09	2012-01-31	The General Hospital Corporation	Protein conjugates with a water-soluble biocompatible, biodegradable polymer
PL211872B1 (pl)	2000-03-31	2012-07-31	Purdue Research Foundation	Kompozycja farmaceutyczna
FR2809106A1 (fr) *	2000-05-17	2001-11-23	Istac	Polypeptide ro/ssa-like et ses fragments et polynucleotides codant lesdits polypeptides et applications therapeutiques
EP1414517A4 (en) *	2001-06-26	2008-02-06	Photomed Technologies Inc	Multiple wavelength illuminator
PH12012502440A1 (en)	2001-06-26	2013-06-17	Amgen Inc	Antibodies to opgl
KR20040053136A (ko) *	2001-09-28	2004-06-23	펄듀 리서치 파운데이션	리간드-면역원 공액체를 이용한 치료 방법
US20030097409A1 (en) *	2001-10-05	2003-05-22	Hungchou Tsai	Systems and methods for securing computers
CA2824167C (en)	2002-09-06	2018-09-25	Amgen Inc.	Therapeutic human anti-il-1r1 monoclonal antibody
AU2003299971A1 (en) *	2002-12-30	2004-07-29	Amgen Inc.	Combination therapy with co-stimulatory factors
US7546638B2 (en) *	2003-03-18	2009-06-09	Symantec Corporation	Automated identification and clean-up of malicious computer code
KR20070005550A (ko)	2003-11-17	2007-01-10	바이오마린 파머수티컬 인크.	대사 장애 치료를 위한 조성물 및 방법
WO2006055511A2 (en) *	2004-11-17	2006-05-26	Biomarin Pharmaceutical Inc.	Stable tablet formulation of tetrahydrobiopterin
AR056806A1 (es)	2005-11-14	2007-10-24	Amgen Inc	Moleculas quimericas de anticuerpo rankl- pth/ pthrp
US8168164B2 (en) *	2006-02-03	2012-05-01	Purdue Research Foundation	Targeted conjugates and radiation
US7833527B2 (en)	2006-10-02	2010-11-16	Amgen Inc.	Methods of treating psoriasis using IL-17 Receptor A antibodies
EP2217258B1 (en)	2007-11-14	2014-03-26	General Regeneratives Limited	Use of interleukin-1 receptor antagonist as a myeloprotective agent
TW201117824A (en)	2009-10-12	2011-06-01	Amgen Inc	Use of IL-17 receptor a antigen binding proteins
CN101690801B (zh)	2009-10-26	2012-08-01	上海交通大学	白细胞介素-1受体拮抗剂的用途及其药物组合物
WO2013016220A1 (en)	2011-07-22	2013-01-31	Amgen Inc.	Il-17 receptor a is required for il-17c biology
US9216178B2 (en)	2011-11-02	2015-12-22	Biomarin Pharmaceutical Inc.	Dry blend formulation of tetrahydrobiopterin
US20160000936A1 (en)	2014-06-10	2016-01-07	Abbvie Inc.	Biomarkers for inflammatory disease and methods of using same
US10041044B2 (en)	2016-07-29	2018-08-07	Trustees Of Boston University	Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
WO2020035482A1 (en)	2018-08-13	2020-02-20	Iltoo Pharma	Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
EP4526469A1 (en)	2022-05-16	2025-03-26	Institut National de la Santé et de la Recherche Médicale	Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation
EP4411592B1 (de)	2023-02-06	2025-04-02	Sick Ag	Verfahren zum lesen eines optischen codes und optoelektronischer codeleser

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK585886A (da) *	1985-12-24	1987-06-25	Takeda Chemical Industries Ltd	Immunstimulerende middel og anvendelse deraf
IL83350A0 (en) *	1986-08-13	1987-12-31	Takeda Chemical Industries Ltd	Pharmaceutical compositions comprising interleukin and intterferon active substances
GB8803365D0 (en) *	1988-02-13	1988-03-16	Ciba Geigy Ag	Antiviral combination

1994
- 1994-03-21 PT PT94910445T patent/PT689449E/pt unknown
- 1994-03-21 US US08/522,342 patent/US5932208A/en not_active Expired - Fee Related
- 1994-03-21 DE DE69431620T patent/DE69431620T2/de not_active Expired - Fee Related
- 1994-03-21 CA CA002157758A patent/CA2157758A1/en not_active Abandoned
- 1994-03-21 EP EP94910445A patent/EP0689449B1/fr not_active Expired - Lifetime
- 1994-03-21 WO PCT/FR1994/000307 patent/WO1994021275A1/fr not_active Ceased
- 1994-03-21 DK DK94910445T patent/DK0689449T3/da active
- 1994-03-21 AT AT94910445T patent/ATE226828T1/de not_active IP Right Cessation
- 1994-03-21 JP JP52072694A patent/JP3723206B2/ja not_active Expired - Fee Related
- 1994-03-21 AU AU62856/94A patent/AU6285694A/en not_active Abandoned
- 1994-03-21 ES ES94910445T patent/ES2187520T3/es not_active Expired - Lifetime

Also Published As

Publication number	Publication date
AU6285694A (en)	1994-10-11
DE69431620T2 (de)	2003-07-03
DK0689449T3 (da)	2003-03-03
JP3723206B2 (ja)	2005-12-07
WO1994021275A1 (fr)	1994-09-29
EP0689449B1 (fr)	2002-10-30
CA2157758A1 (en)	1994-09-29
EP0689449A1 (fr)	1996-01-03
JPH08511235A (ja)	1996-11-26
US5932208A (en)	1999-08-03
DE69431620D1 (de)	2002-12-05
ATE226828T1 (de)	2002-11-15
ES2187520T3 (es)	2003-06-16

Publication	Publication Date	Title
PT689449E (pt)	2003-03-31	Composicoes para aplicacao em terapeutica humana caracterizadas pela associacao de um peptido de muramilo a uma citoquina
Trinchieri et al.	1992	Natural killer cell stimulatory factor (NKSF) or interleukin-12 is a key regulator of immune response and inflammation
Stern et al.	1996	Interleukin-12 an integral cytokine in the immune response
Lacey et al.	1993	IL-1-induced murine osteoblast IL-6 production is mediated by the type 1 IL-1 receptor and is increased by 1, 25 dihydroxyvitamin D3.
IT1261949B (it)	1996-06-04	Composizione terapeutica a base di interferone umano, impiego di interferone umano in tale composizione e relativo metodo.
WO2002068470A3 (en)	2002-12-05	Interferon-alpha induced gene
KR950700333A (ko)	1995-01-16	개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로부터의 제조 방법(improved alpha interferon composition and method for its production from human peripheral blood leukocytes)
Lefort et al.	1995	IL-13 and IL-4 share signal transduction elements as well as receptor components in TF-1 cells
BRPI0409910A (pt)	2006-04-25	métodos para o tratamento de doenças relacionadas com interleucina-6
GR3033498T3 (en)	2000-09-29	NEW hIL-4 MUTANT PROTEINS USED AS ANTAGONISTS OR PARTIAL AGONISTS OF HUMAN INTERLEUKIN 4
GR3032037T3 (en)	2000-03-31	Immunogen compounds having specifically an anti-cytokine effect, method of preparation, pharmaceutical compositions and kits containing them
IE58963B1 (en)	1993-12-01	Y-ifn as active substance for inhibiting (preventing) degradation process in bone
DK0669979T3 (da)	2006-03-06	C-C CKR-1, kemokinreceptor
DK0613499T3 (da)	1998-09-23	Humame IT-4-mutantproteiner
Yoshikai et al.	2000	The role of interleukin 15 in mounting an immune response against microbial infections
ITMI922331A0 (it)	1992-10-09	Uso di paratormone suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto protermine ed in generale per il trattamento della gestazione
Morhenn	1986	The etiology of lichen planus: a hypothesis
Tahara et al.	2007	Systemic sclerosis after interferon alphacon-1 therapy for hepatitis C
YU199691A (sh)	1994-06-24	Receptor za humani interleukin-5
CA2388338A1 (en)	2001-05-03	Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
Suzuki et al.	2001	Serum levels of interleukin 15 in patients with rheumatic diseases.
NO971378L (no)	1997-06-05	Cytokin betegnet LERK-6
DE69127974D1 (de)	1997-11-20	Peptide und deren verwendung
BR0313503A (pt)	2005-06-21	Método de tratamento de sìndrome das pernas inquietas, uso do antagonista de receptor da adenoina a2a, agente terapêutico para sìndrome das pernas inquietas, e, método de tratamento da mioclonia noturna
BR9713096A (pt)	2000-10-24	Lactação bovina associada à proteìna imunotrópica (cd14), gene codificado e aplicação na ativação de célula b